An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) is now available. ResMed Inc has ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 millionNote: A webcast of ...

ResMed Inc. closed 8.55% short of its 52-week high of $263.05, which the company reached on January 30th.

In a report released on January 31, Davinthra Thillainathan from Goldman Sachs maintained a Buy rating on Resmed Inc CHESS Depositary Interests ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability. The great quarter was driven by high ...

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE ...